171050-01-4Relevant articles and documents
Fab I inhibitors
-
, (2008/06/13)
Compounds of the formula (I) are disclosed which are FabI inhibitors and are useful in the treatment bacterial infections: wherein: R1is H, C1-6alkyl or Ar—C0-6alkyl; R2is H, C1-6alkyl, Ar—C0-6alkyl, HO—(CH2)n— or R′OC(O)—(CH2)n—; R3is A—C0-4alkyl, A—C2-4alkenyl, A—C2-4alkynyl, A—C3-4oxoalkenyl, A—C3-4oxoalkynyl, A—C1-4aminoalkyl, A—C3-4aminoalkenyl, A—C3-4aminoalkynyl, optionally substituted by any accessible combination of one or more of R10or R7; R5is H, C1-6alkyl, Ar—C0-6alkyl or C3-6cycloalkyl-C0-6alkyl; A is H, C3-6cycloalkyl, Het or Ar; R7is —COR8, —COCR′2R9, —C(S)R8, —S(O)kOR′, —S(O)kNR′R″, —PO(OR′), —PO(OR′)2, —B(OR′)2, —NO2, or tetrazolyl; R8is —OR′, —NR′R″, —NR′SO2R′, —NR′OR′, or —OCR′2CO(O)R′; R9is —OR′, —CN, —S(O)rR′, —S(O)kNR′2, —C(O)R′, C(O)NR′2, or —CO2R′; R10is H, halo, —OR11, —CN, —NR′R11, —NO2, —CF3, CF3S(O)r—, —CO2R′, —CONR′2, A—C0-6alkyl-, A—C1-6oxoalkyl-, A—C2-6alkenyl-, A—C2-6alkynyl-, A—C0-6alkyloxy-, A—C0-6alkylamino- or A—C0-6alkyl —S(O)r—; R11is R′, —C(O)R′, —C(O)NR′2, —C(O)OR′, —S(O)kR′, or —S(O)kNR′2; R′ is H, C1-6alkyl, Ar—C0-6alkyl or C3-6cycloalkyl-C0-6alkyl; R″ is R′, —C(O)R′ or —C(O)OR′; R′″ is H, C1-6alkyl, Ar—C0-6alkyl, HO-(CH2)2—, R′C(O)—, (R′)2NC(O)CH2— or R′S(O)2—; X is H, C1-4alkyl, OR′, SR′, C1-4alkylsulfonyl, C1-4alkylsulfoxyl, —CN, N(R′)2, CH2N(R′)2, —NO2, —CF3, —CO2R′, —CON(R′)2, —COR′, —NR′C(O)R′, F, Cl, Br, I, or CF3S(O)r—; k is 1 or 2; m is 1, 2 or 3; n is 1 to 6; and r is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.
Bicyclic fibrinogen antagonists
-
, (2008/06/13)
PCT No. PCT/US95/00248 Sec. 371 Date Jul. 3, 1996 Sec. 102(e) Date Jul. 3, 1996 PCT Filed Jan. 9, 1995 PCT Pub. No. WO96/18619 PCT Pub. Date Jul. 13, 1995Certain compounds within formula (I) are inhibitors of platelet aggregation: wherein A1 is NH or CH2;
